此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估基于 SrRNA 的带状疱疹疫苗 JCXH-105 的 2 期研究

2026年11月3日 更新者:Immorna Biotherapeutics, Inc.

一项 2 期、随机、三盲、活性对照研究,旨在评估试验性带状疱疹 (HZ) 疫苗 JCXH-105 在 50 岁以上健康受试者中的安全性和免疫原性

The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles).

Subjects will be randomized to receive either JCXH-105 or Shingrix.

研究概览

详细说明

This Phase 2 study plans to enroll a total of 460 subjects.

This will be an active-controlled study in healthy male and/or female subjects 50 years of age or older. Subjects will be randomized 1:1 to receive either JCXH-105 or Shingrix. The study vaccine will be administered in two doses approximately 2 months apart. The subject will receive a single intramuscular (IM) injection of JCXH-105 or Shingrix on Day 1 (Dose 1) and again on Day 61 ± 7 days (Dose 2). For each subject, Dose 1 and Dose 2 are the same study vaccine based on randomization on Day 1. A total of 460 subjects will be enrolled into this trial and vaccinated with either JCXH-105 (n=230) or Shingrix (n=230).

研究类型

介入性

注册 (实际的)

467

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Tucson、Arizona、美国、85704
        • Noble Clinical Research
    • California
      • Long Beach、California、美国、90805
        • Long Beach Research Institute
    • Illinois
      • Chicago、Illinois、美国、60652
        • DM Clinical Research - Chicago
    • Nebraska
      • Omaha、Nebraska、美国、68114
        • Quality Clinical Research
    • New Jersey
      • Jersey City、New Jersey、美国、07306
        • DM Clinical Research - New Jersey
    • South Carolina
      • Charleston、South Carolina、美国、29407
        • Delricht Research
    • Texas
      • Prosper、Texas、美国、75078
        • Delricht Research
      • Sugar Land、Texas、美国、77478
        • DM Clinical Research - Sugarland

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Sex: Male or female; female subjects may be of childbearing potential, of nonchildbearing potential, or postmenopausal.
  • Age: ≥ 50 years of age at screening.
  • Status: Healthy subjects.
  • Subjects must agree to not be vaccinated with any HZ vaccine while participating in this study.
  • Subjects must agree to not be vaccinated with any RNA-based vaccines (e.g., Spikevax, Comirnaty, etc.) 30 days before Dose 1 through 30 days after Dose 2 (a 4-month period).

Key Exclusion Criteria:

  • Subjects with a history of HZ within the past 10 years or current diagnosis of HZ.
  • Previous vaccination against HZ.
  • Subjects with any respiratory illness deemed clinically relevant by the Investigator within the past month OR hospitalization >24 hours for any reason within the past month prior to the first vaccine administration (JCXH-105 or Shingrix).
  • Subjects who are acutely ill or febrile with body temperature ≥ 38.0º Celsius/100.4º Fahrenheit 72 hours prior to or at the Screening visit or on Day 1 pre-dose. Subjects meeting this criterion may be rescheduled within an allowable window with approval from the Sponsor.
  • Subjects with history or current diagnosis of congenital or acquired immunodeficiency/immunocompromising/immunosuppressive conditions, asplenia, or recurrent severe infections. Certain immune-mediated conditions (e.g., Hashimoto thyroiditis) that are well controlled and stable are allowed.
  • Subjects with history of myocarditis or pericarditis, or with AEs (including anaphylaxis and severe hypersensitivity) after mRNA vaccination that are in nature and severity beyond the common expected AEs and necessitating medical intervention.
  • Subjects who received any non-live vaccine within 14 days prior to Day 1 (first dose of JCXH-105 or Shingrix).
  • Subjects who received within 28 days prior to Day 1 (first dose of JCXH-105 or Shingrix): (1) Any live vaccine, (2) Immunomodulators or immune-suppressive medication, (3) Granulocyte or granulocyte-macrophage colony-stimulating factor, (4) Three or more consecutive days of systemic corticosteroids. Note: subjects on stable-dose steroid replacement (for chronic disease such as iatrogenic deficiency) of prednisone ≤10 mg/day or equivalent are allowed and (5) Other investigational agents or devices.
  • Subjects receiving systemic antiviral therapy.
  • Subjects with a positive screening test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, anti-human HIV-1 and 2 antibodies, or syphilis.
  • Subjects with a positive screening test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Investigational Product

Participants randomized to this arm will be given the investigational product (JCXH-105).

IM injection

有源比较器:Active Control

Participants randomized to this arm will be given the FDA approved Shingrix.

IM injection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
SAE Frequency
大体时间:Day 1 - Day 241 (Week 34)

Frequency of SAEs characterized by type, severity, duration, and relationship to the vaccine recorded from Day 1 post-vaccine administration through follow-up completion.

Day 1 - Day 241 (Week 34)
Solicited local reaction frequency
大体时间:Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)

Occurrence of solicited local injection site reactions characterize by frequency, severity, and duration within 7 days after each vaccine administration.

Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
Solicited systemic reaction frequency
大体时间:Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)

Occurrence of solicited systemic reactions characterize by frequency, severity, and duration within 7 days after each vaccine administration.

Day 1 - Day 7 (After Dose 1), Day 1 - Day 7 (After Dose 2)
AE Frequency
大体时间:Day 1 - Day 241 (Week 34)

Adverse events (AEs) including unsolicited AEs and any AEs leading to discontinuation of study vaccine or withdrawal from the study, characterized by frequency, severity, duration, and relationship to the vaccine from Day 1 post-vaccine administration through follow-up completion.

Day 1 - Day 241 (Week 34)
AESIs Frequency
大体时间:Day 1 - Day 241 (Week 34)

AESIs characterized by frequency, severity, duration, and relationship to the vaccine from Day 1 post-vaccine administration through follow-up completion.

Day 1 - Day 241 (Week 34)
Medically Attended AE Frequency
大体时间:Day 1 - Day 241 (Week 34)

Medically attended AEs (MAAEs) characterized by frequency, severity, duration, and relationship to the vaccine from Day 1 post-vaccine administration through follow-up completion.

Day 1 - Day 241 (Week 34)
Immune-Mediated Adverse Events of Special Interest Frequency
大体时间:Day 1 - Day 241 (Week 34)

Immune-mediated adverse events of special interest (imAESIs) characterized by frequency, severity, duration, and relationship to the vaccine (JCXH-105 or Shingrix) recorded from Day 1 post-vaccine administration through follow-up completion.

Day 1 - Day 241 (Week 34)
gE-Specific CD4+ T cell Response Rate
大体时间:Day 1 - Day 89 (Week 13)

Response Rate is defined at the percentage of subjects with ≥ 2 folds increase of gE-specific CD4+ T cells expressing 2 or more markers of activation (IFN-γ, IL-2, TNFα, and CD40L) in PBMCs analyzed with flow cytometry with ICS on Day 89 as compared to baseline (Day 1 pre-dose).

Day 1 - Day 89 (Week 13)

次要结果测量

结果测量
措施说明
大体时间
Cellular immunogenicity of JCXH-105
大体时间:Day 1 - Day 241 (Week 34)

Frequency of glycoprotein E (gE)-specific CD4+ T cells expressing 2 or more markers of activation (IFN-γ, IL-2, TNF-α, and CD40L) in PBMCs analyzed by flow cytometry with ICS on Day 29, Day 89, and Day 241 as compared to baseline (Day 1 pre-dose).

Day 1 - Day 241 (Week 34)

其他结果措施

结果测量
措施说明
大体时间
Cellular Immunogenicity of JCXH-105
大体时间:Day 1 - Day 241 (Week 34)

Frequency of gE-specific CD8+ T cells expressing 2 or more markers of activation (IFN-γ, IL-2, TNF-α, and CD40L) in PBMCs analyzed by flow cytometry on Day 29, Day 89, and Day 241 as compared to baseline (Day 1 pre-dose).

Day 1 - Day 241 (Week 34)
Humoral immunogenicity of JCXH-105
大体时间:Day 1 - Day 241 (Week 34)

Changes in serum of anti-gE-specific antibody geometric mean titers (GMTs) analyzed with enzyme-linked immunosorbent assay (ELISA) on Day 29, Day 89, and Day 241 as compared to baseline (D1 pre-dose).

Day 1 - Day 241 (Week 34)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年10月16日

初级完成 (实际的)

2026年2月19日

研究完成 (估计的)

2027年3月1日

研究注册日期

首次提交

2024年8月29日

首先提交符合 QC 标准的

2024年8月29日

首次发布 (实际的)

2024年9月3日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅